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SAFETY AND EFFICACY OF IRON SUCRSE IN 
MILD TO MODERATE ANAEMIA. 
ABSTRACT  
Background & Objectives : Iron deficiency anaemia (IDA) is the most 
common nutritional deficiency in pregnancy. Prophylactic oral iron is 
recommended during pregnancy to meet the increased requirement. 
Pregnant women with mild to moderate anaemia are to be treated with 
parenteral iron therapy. This study was undertaren to evaluate the safety 
and efficacy of intravenous iron sucrose complex (ISC) given to pregnant 
women with IDA methods : A prospective Randomised control study was 
conducted (August 2015 to July 2016) in the department of obstetrics & 
gynaecology, Government  Theni Medical College, Theni. One hundred 
pregnant women with hemoglobin between 7-9 g % with diagnosed iron 
deficiency attending antenatal clinic were given intravenous iron sucrose 
in a dose of 200mg twice weekly schedule after calculating the dose 
requirement. 
 
RESULTS : 
The mean hemoglobin raised from 7.51 (+ or -) 0.6 g  to 10.9 (+ or -)  0.8 
g% after three weeks of therapy. Retculocyte count increased after 3 
weeks of starting therapy (from 1.165 to 4.098). Other parameters 
including red cell indices were also improved significantly No major side 
effects or anaphylactic reactions were noted during study period.  
INTERPRETATION & COUCLUSIONS:  
parameters iron therapy was effective in increasing hemoglobin and other 
hematological parameters in pregnant women with mild to moderate 
anaemia. 
 
KEY WORDS : 
Anaemia – iron deficiency – iron sucrose complex – parenteral iron 
therapy – Reticulocyte count. 
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                                            INTRODUCTION 
Anemia is an important problem of the developing country more so in the 
pregnant period. Of all types of anemia, nutritional anemia is very 
common and iron deficiency anemia is the most common of these 
nutritional anemias.  
 
The prevalence of iron deficiency anemia is estimated to be around 18% 
in developed countries and a staggering 35-75% in developing countries 
as per WHO report. As against the worldwide incidence, Indian incidence 
varies between 33-89%. Anemia accounts for about 80% of the global 
maternal mortality ratio. 
 
Various factors contribute the increased incidence of anemia in India as 
compared to the world. These factors include: 
1. early marriage 
2. teenage pregnancy 
3. multiple pregnancies 
4. inadequate spacing between pregnancies 
5. reduced intake of iron and folic acid 
6. elevated incidence of worm infestation 
7. poor nutrition 
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         Cochrane data review1 reported anemia as a serious global problem 
affecting 52% and 23% of pregnant women in developing and developed 
countries respectively.  
      
     WHO defines iron deficiency anemia as hemoglobin <11gm%, in 
India the ICMR classification of anaemia (IDA) 8-11g% as mild, 5-
8gm% as moderate  and <5gm% as severe anaemia. 
 
 
Anemia in pregnancy is a major issue as it results in low birth weight 
babies, preterm deliveries and preterm delieveres. anemia detected during  
pregnancy can be a  mild condition which can be completed treated if 
diagnosed early. however anemia becomes life threatening to both mother 
and fetus if left untreated. 
 
Commonly identified cause of anemia in pregnancy is nutritional anemia 
,among which iron deficiency is the leading cause accounting almost 80% 
of anemic population followed by, folate deficiency and vitamin B12 
deficiency anemia. It  affects 52% of pregnant women in developing  
countries and 23% in developed countries. Among these 43% of women 
from developing countries and 12 % from developed countries are 
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already anemic pre-conceptionally. Who has estimated 16800 to 28000 
reproductive age women die annually all around the world  due to anemia 
and its related cause. 
 
It is a major contributory factor to maternal morbidity, mortality and 
perinatal mortality rate. women between 18-40 yrs have prevalence of fe 
deficiency anemia of 11 % and non pregnant women of same age with 
5% 
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ANEMIA: 
 
Anemia is a condition of insufficient red blood cells in the human body. 
There are various types of anemia world over.  
 
The most common of these types of anemia is iron deficiency anemia 
which accounts for 15 to 25% of the overall pregnancies complicated by 
anemia.  
 
Folate deficiency can manifest as macrocytic anemia. This folic acid is an 
essential micronutrient, the deficiency of which manifests as neural tube 
defects. Diet rich in folic acid maybe leafy vegetables, bananas, legumes.  
Vitamin B12 is another important vitamin that can present with anemia 
on its deficiency.  
 
There are various causes for anemia, and the occurrence of anemia is 
most commonly in second trimester because of the associated 
hemodilution due to disproportionate rise in plasma concentration 
compared to RBCs.  
7  
 
An anemic mother can be identified by her history of getting tired often, 
becoming breathless, unable to perform her routine daily work, 
occasional giddiness.  
On examination the mother presents with generalized pallor of the bulbar 
conjunctiva, hard palate and nails. The diagnosis of anemia is confirmed 
by estimating her hemoglobin values. Furthermore red cell indices like 
MCV, MCH and MCHC can be done to identify whether the anemia is 
microcytic or macrocytic, hypochromic or normochromic.  
A smear study can be done to examine the red cells under microscope and 
confirm the variations in size, colour and shape of the RBCs.  
This is then followed up with unusual tests like stool examination for 
occult blood, parasitic ova and cysts to identify other causes of anemia 
and correct them with antiparasitic medication. An ultrasound 
examination of the maternal abdomen can be done to identify rare 
medical disorders causing anemia like hepatospleomegaly when the 
anemia is refractory to iron treatment.  
The next in line of investigations would be to asses her cardiac status to 
ensure the heart is capable of taking the volume overload status of 
pregnancy. Once basic investigations are done, anemia being a clinical 
diagnosis, iron supplementation is started earlier. The laboratory reports 
are needed to assess the severity of anemia and thereby decide upon the 
mode of iron administration to the patient.   
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IRON DEFICIENCY: 
Iron is essential element present in Hb molecule , as its the oxygen 
carrying pigment in blood. Total iron requirement  during pregnancy is 
900mg with range of 700-1400mg of which about 500-600 mg is 
accounted by uterus and its content.150-200mg loss during delievery and 
same amount through lacactation. There is increased maternal 
haemoglobin mass which consumes about 500mg .it is returned to stores 
after delievery. A total iron defecit of about 600-700mg occurs during 
pregnancy.  
Parenteral iron is indicated in women who donnot tolerate oral iron or 
poor response to oral therapy which 0.8 g% per week .The rate of 
response to iron therapy is the same whether given orally or parentrally. 
However parenteral iron eliminate the risk of non compliance  and saves 
critical time in case of non-responders in late gestation. 
oral iron should be discontinued before starting parenteral otherwise the 
Fe receptors sites are competitively inhibited leading to increased iron 
toxicity leading to Fe circulating iron. 
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Stages of development of iron deficiency anemia: 
 
1. stage of storage iron depletion 
      It leads to early functional iron deficiency which shows that iron 
supplt to bone marrow and other tissues is margially inadequate.still there 
is no anemia 
 
2. iron deficient erythropoisis 
In this stage peripheral smear shows normocytic cells,laboratory 
parameters used to detect this phase are serum transferin saturation,total 
iron binding capacity,erythrocyte zinc protoporphyrin concentration and 
soluble transferrin receptor concentration assay. 
In iron deficieny anemia,se iron 60 microgm per dl  
Total iron binding capacity 400 microgram per dl 
Ratio of( iron/TIBC) × 100 gives transferrin saturation percentage 
 
In anemia of chronic disorders ,se ferritin and TIBC are decreased. 
Whereas in fe deficiency anemia,serum ferritina nd transferin saturation 
percentage is decreased but TIBC increased 
 
Soluble transferin receptor concentration is increased in iron deficiency 
and hematopoisis.but reamisn normal in anemia of chronic disorders. 
10  
 
Stage 3. 
The blood picture sows reduction in Hb ,PCV,MCV and MCHC. 
The picture is microcytic hypochromic 
New cells are being generated at normal rate.reticulocyte count shows 
little deviation from normal.cells are anisocytosis and polychromasia. 
Red cell distribution width is a feature to differentiate between iron 
deficiency anemia and thalassemia. 
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Cellular iron metabolism 
 
Fe sucrose is second generation IV iron preparation ,safe with few side 
effects with minimal allergic reactions with no reported fatal death.In this 
study , a group of 100 anemic mothers were studied and the efficacy and 
safety of iron sucrose injections is documented. 
                              
IRON REQUIREMENT IN PREGNANCY 
 
   The iron requirement in various stages of pregnancy are: 
 
  Early pregnancy   - 2.5 mg/ day  
  20-32 Weeks        - 5.5 mg / day 
  32 weeks onwards - 6. 8 mg / day 
 
There are various enzymes in the human body in which iron plays a 
significant role. These enzymes are hemoglobin, myoglobin and some 
enzymes. Iron serves varied functions in all these enzymes like oxygen 
carrier, catalyst for oxygenation and hydroxylation, electon carrier 
through the Fe++/Fe+++ cycle.  
Various changes occur in pregnancy which result in iron deficiency state 
in pregnancy. It could be because of 
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1. Poor iron content in diet 
2. Reduced iron stores since early days 
3. Supporting the nutritional requirement of baby and placenta 
 
 
CLINICAL FEATURES OF IRON DEFICIENCY 
Iron deficiency anemia manifests with various symptoms. The clinical 
features are mild initially. The American Society of Hematology says 
symptoms are so mild initially that many people do not realize they have 
anemia unless it is identified incidentally on a routine blood test.   
 
The symptoms of moderate to severe iron deficiency anemia include: 
Easy fatigablity 
generalized weakness 
generalized pallor of skin and nails 
koilonychia 
dyspnea 
giddiness 
PICA 
beefy smooth tongue 
cold hands and feet 
palpitations 
13  
 
brittle nails 
headaches  
 
Effects of anemia on mother 
 
       Anemia is  a major contributor to maternal mortality.case fatality rate 
1 – 50% depending on the obstetric care and severity of anemia.cardiac 
failure is an important cause of maternal mortality in severe anemia.all 
complications of pregnancy are aggravated by anemia .cardiac patiemts 
suffer from greatly incread dyspnea.immune system is suppressed which 
leads to increased susceptibility to infections ranging from asymptomatic 
bacteriuria  to sepsis. 
 
     Antepartum complications associated with and aggravated by anemia 
are preeclapsia and antepartum hemorrhage. 
     During intrapartum period,uterine inertia,maternal exhaustion and 
postpartum hemorrhage are more common. 
 
     During puerperium ability to cope up with infection is impaired. 
postnatal recovery is also retarted leading on to puerperal sepsis, thrombo 
emboloism, sub-involution of uterus ,delayed wound healing  and  
lactational failure. 
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EFFECT OF ANEMIA ON FETUS 
Effect on fetus depend son severity of anemia. low birth weight incidence 
increases two fold and perinatal ortalit increases three fold when Hb is 
less than 7 g%. 
 
IUGR and low birth weight leads to poor growth trajectory in infancy, 
childhood and adolescence. 
 
Geststaional period at which fetus is exposed to anemia is important in 
deciding the perinatal outcome. anemia during first trimester have great 
adverse affect on fetus. 
 
Physiological hemodilution of pregnancy reaches its nadir at the end of 
second trimester and early third trimester which improves placental blood 
flow when the fetal requirements are greatest. 
 
Moderate anemia before 28 weeks has been associated with increased 
still birth rate.the fetus extracts its iron from maternal storage. so if 
maternal storage is deficient fetal iron source becomes inadequate. so 
neonate is at full risks of developing anemia 
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LABORATORY DETECTION OF ANEMIA 
Complete blood cell (CBC) test 
A complete blood cell (CBC) test is usually the first test . 
CBC test measures the amount of all components in the blood, including: 
 Red blood cells (RBCs) and its indices 
 White blood cells (WBCs) 
 Hemoglobin 
 Platelets 
 Hematocrit level, which is the percent of blood volume that is 
made up of RBCs 
          the hemoglobin level 
          the size of RBCs 
The CBC test provides information not only about the deficicency status 
of Hb but also about the type of anemia through various  red cell indices 
like MCV,MCHC 
 
A normal hematocrit range is 34.9 to 44.5 percent for adult women and 
38.8 to 50 percent for adult men. The normal range for hemoglobin is 
12.0 to 15.5 grams per deciliter for an adult woman and 13.5 to 17.5 
grams per deciliter for an adult man. In iron deficiency anemia, the 
hematocrit and hemoglobin levels are low. Also, RBCs are usually 
smaller in size than normal. 
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Other tests 
iron level in blood 
RBC size and color 
RBCs are pale in color if they’re deficient in iron. 
ferritin levels 
Ferritin is a protein that helps with iron storage. Low levels of ferritin 
indicate low iron storage. 
total iron-binding capacity (TIBC) 
Transferrin is a protein that transports iron. A TIBC test is used to 
determine the amount transferrin that’s carrying iron. 
 
Diet 
Diets high that include the following foods can help treat or prevent iron 
deficiency: 
red meat 
dark green, leafy vegetables 
dried fruits 
nuts 
iron-fortified cereals 
Additionally, vitamin C helps your body absorb iron. If you’re taking iron 
tablets, a doctor might suggest taking the tablets along with a source of 
vitamin C, like a glass of orange juice or citrus fruit. 
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Iron supplements 
 
Iron tablets can help restore iron levels in your body. Iron tablets should 
be taken on empty stomach to enable the body to absorb them better. 
When there is associated nausea and vomiting, these tablets may be taken 
with meals. These iron tablets need to be taken for long duration to have a 
significant improvement in iron levels in the body. Iron supplements may 
cause constipation or stools that are black in color. 
 
Various parenteral iron preparations are available in the market, which 
can be administered either intravenously or intramuscularly. Initially, iron 
dextran and iron sorbitol citrate were available in the market for usage. 
But these formulations required administering a testdose as there was a 
propensity to cause severe anaphylactic reactions.  
 
Iron sorbitol citric acid and iron dextran were the commonly used 
parenteral preparations for a long period of time. But they had an 
anaphylactic reaction adverse effect that was highly unpredictable. And 
these preparation also had a multitude of local and systemic side effects 
which limited their widespread use. Despite all these side effects these 
formulations were capable of providing some improvement in the 
hemoglobin status of women suffering from anemia.   
18  
 
The next to enter the market was intravenous preparation of iron sucrose 
which significantly improved the hematological indices with negligible 
side effects or anaphylaxis. This was hence considered a safe alternative 
for iron supplementation.  
 
The Cochrane database2 suggested that intravenous administration of iron 
sucrose had a better outcome hematologically with fewer side effects 
when compared to imtramuscular iron injections. 
  
        A Cochrane review was conducted in 20073 by performing a 
randomized controlled trial to evaluate the effects of treating the iron 
deficiency anemia during pregnancy. This study concluded that blood 
transfusion as a method to correct iron deficiency anemia has a 
significant risk of infection transmission to the receiver like parasitic 
infections, viral infections such as Hepatitis, HIV, Trypanosomiasis, 
bovine spongiform encephalitis. The risk of transmitting these infections 
persisted despite screening of blood. Moreover, in addition to infection 
risk there was transfusion associated risks like TRALI. 
 
The iron supplementation to correct anemia is important as antenatal 
anemia can result in postnatal anemia in about 27% of mothers. 
Postpartum anemia has the associated complication of leading on to 
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depression, prolonging the duration of hospital stay, and affect the 
lactation ad thereby the infant development.  
         
Hence iron supplementation with intravenous preparations is a safe 
option to correct iron deficiency anemia and ensure better maternal health 
and reduce maternal mortality and improve perinatal outcome.. 
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IRON SUCROSE: 
Iron sucrose is brown in colour, an aqueous solution, made of 
polynucleariron hydroxide with sucrose. This drug is administered 
intravenously. The molecular weight of this compound is about 34,000 – 
60,000 daltons. The formula is  
 
[Na2Fe5O8(OH) •3(H2O)]n •m(C12H22O11) 
 
Where n is the degree of iron polymerization and m is the number of 
sucrose molecules associated with the iron (III)-hydroxide. 
One ml of iron sucrose injection contains 20mg elemental iron. This 
compound is available as vials of 5 ml each, which need to be 
administered in a single dose. One vial contains 100mg of elemental iron. 
The sucrose content is about 30% w/v, with pH of 10.5 to 11. There are 
no added preservatives. The osmolarity is 1250mOsmol/L.  
 
Clinical Pharmacology 
Pharmacodynamics & Pharmacokinetics: 
 
After the intravenous administration, this iron sucrose splits into iron and 
sucrose in the reticuloendothelial system. Iron undergoes first order 
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pharmacokinetics, and the half life of the drug is 6 hours. Among the 
volume of distribution, 10.0L exists in nonsteady state and 7.9L exists as 
steady state. The clearance of iron from the body depends on stores of 
iron. Hence clearance of iron following iron sucrose injection is more 
rapid in iron deficient individulas compared to healthy individuals.  
Distribution:  
Iron sucrose administration in a healthy adult causes sucrose to enter into 
blood and a small  percentage in the extravascular compartment. Some 
iron enters into liver, spleen, bone marrow and this store of iron is not 
available for usage. The iron gets trapped and contributes to non 
reversible volume of distribution. 
Metabolism and Elimination:  
After splitting into iron and sucrose, the sucrose component and some 
iron gets excreted in urine 
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Table I. Baseline hematological parameters and effect of iron sucrose 
therapy  
Parameters     Baseline 2 wk 4 wk 8 wk P value  
 
Mean Hb (g%)  
7.63 ± 
0.61  
7.89 ± 
0.60  
9.90 ± 
0.80  
11.20 ± 
0.73  
0.001  
Serum iron (μg/dl)  
32.72 ± 
5.00  
42.94 ± 
9.4  
59.11 ± 
13.7  
82.42 ± 
12.5  
0.001  
TIBC (μg/dl)  
354.2 ± 
37.7  
328.8 ± 
14.8  
320.96 ± 
11.3  
315.5 ± 
11.6  
0.001  
Serum ferritin (μg/l)  
11.2 ± 
4.7  
17.64 ± 
9.3  
25.60 ± 
10.90  
69 ± 
23.1  
0.001  
Reticulocyte count (%)  
1.50 ± 
0.60  
4.6 ± 
0.8  
4.8 ± 2.1  
5.5 ± 
1.8  
0.001  
Mean corpuscular vol. ( ) 
67.24 ± 
5.0  
76 ± 4.5  
79.3 ± 
3.2  
85 ± 2.3  0.001  
Mean corpuscular hemoglobin 
(MCH) (pg)  
22.3 ± 
2.6  
24 ± 3.2  34 ± 2.2  44 ± 3.2  0.001  
Mean corpuscular hemoglobin 
concentration (MCHC) (g/dl)  
26.5 ± 
1.9  
31 ± 2.3  40 ± 3.2  56 ± 2.4  0.001  
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IRON METABOLISM 
          Most of the iron within the body is found in haemoglobin within 
erythrocytes (about 1800mg of iron).Iron is stored in macrophages (and a 
lesser extent in hepatocytes),which represents the storage pool o iron 
(about 1600mg of iron). Small amounts of iron are found in myoglobin 
and in plasma (bound to transferrin).Iron is conserved within the body. 
 
        The typical adult human body contains about 3000-4000mg of iron. 
Only about 1mg of iron is lost from the body per day (through blood loss 
or sloughed mucosal epithelial cells) and must be replaced through the 
diet. The majority of iron required by the body is acquired by recycling 
iron from senescent red cells. 
        
  Iron is important in human body because of its occurrence in many 
hematopoitins such as haemoglobin, myoglobin and cytochromes. 
Digested in diet as heme or non heme iron. 
Most of the iron in the diet is in the ferric(Fe3+) form, whereas it is the 
ferrous (Fe2+)form that is absorbed. Fe3+ will be converted to Fe2+ by Fe3+ 
reductase in the brush border of enterocytes 
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       Normally greater proportion of dietary heme iron than non heme iron 
is absorbed reflecting the greater importance of heme as source of 
iron.Almost all iron absorption occurs in the duodenum. 
       
 Iron absorption is facilitated by reducing substances like ascorbic acid. 
Sugars especially fructose increase the absorption and may contribute to 
dietary hemosiderin. Iron absorption is inhibited by alkalies, phosphates, 
phytates.  RDA of iron in menstruating adult female is 1-2mg and in 
pregnancy is 3-5mg. 
       
  Dietary iron is obtained from either inorganic or animal sources. It 
enters intestinal cells via specific transporters which is then used by the 
cell(to form enzymes),stored as ferritin or is transferred to plasma. 
Ferroportins are the specific iron channels which causes the transfer of 
iron from enterocytes to the transport protein, apotransferrin. This is 
facilitated by a protein (with ferroxidase activity) called hephaestin. 
Apotransferrin  binds with iron to form transferrin.       
 
       Hephaestin contains copper, hence copper deficiency will decrease 
iron absorption. Hepcidin is a main iron regulating protein which 
decreases ferroportin and thus decreases iron absorption. Normal value of 
transferrin saturation with iron is 35%. 
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       Heme is transported into the enterocyte by separate heme transporter 
and heme oxidase releases Fe2+ from the heme. A part of Fe2+ is 
converted to Fe3+ and is bound to ferritin. The rest binds to basolateral 
Fe2+ transporter ferroportin(FP),bound to transferrin and stored in the 
body as ferritin and hemosiderin. 
    
         Transferrin does not cross the placenta but gives up its iron in 
chorionic villus. Iron is transferred across the placenta against steep 
concentration gradient, so it is enzyme dependant. 
 
        Erythroid progenitors obtain iron for haemoglobin synthesis from 
plasma transferrin or from recycling of senescent erythrocytes  by 
macrophages in bone marrow, spleen and liver. Iron that is in excess of 
that required for haemoglobin production is stored in macrophages as 
ferritin, which is oxidised to hemosiderin. 
 
       Iron exists in the circulation as transferrin(bound to 
apotransferrin).most the iron is obtained by breakdown of senescent 
RBC(called recycling). red blood cells are phagocytised by macrophages. 
heme and globins are released by proteolytic digestion of 
haemoglobin.the iron is released from hemeporphyrin ring is released.    
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it is converted to bilirubin.In macrophages, ceruloplasmin is a ferroxidase 
and facilitate transport of macrophage iron to transferring. 
 
 
 Erythropoiesis 
Erythropoiesis is the development of mature red blood 
cells.proerythroblast is the first cell of erythroidcells. Then the basophilic 
erythroblast cell.cell continue to become smaller during development. 
The cell now will continue to produehaemoglobin and now it is called 
polychromatophilicerythroblast.cytoplsm begins more eosinophilic now 
at this stage tthe cell is northochromaticerythroblast. thisorthochromic 
erythroblast will then extrude its nucleus and enter circulation as 
reticulocyte. reticulocyte loose their polyribosome and become mature 
red blood cells. 
RBC production starting from stem cells to mature RBC takes bout 25 
days. 
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ERYTHROPOISIS 
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OTHER TYPES OF ANEMIA: 
MEGALOBLASTIC ANEMIA: 
This anemia is caused due to deficiency of vitamin B12 or folic acid in 
the general population. But when megaloblastic anemia is identified in 
pregnancy the cause is most commonly due to deficiency of folic acid. 
 
Mechanism of action: 
Folic acid is an important factor required to convert uridine to thymidine. 
This is a significant step in synthesis of  nucleic acids. When there is 
deficient folic acid in the body, the nucleic acid synthesis is affected and 
cell get inhibited in division and appear macrocytic and hence tha name 
megaloblastic anemia.  
 
The incidence of this variant of anemia is 0.2 to 5%. But the bone 
marrow changes could be a lot higher compared to the clinical 
presentation of megaloblastic anemia.  
 
The megaloblastic red cells undergo rapid destruction and this results in 
compensatory marrow hyperplasia. Also the demand of RBC is increased 
in pregnancy  and further megaloblastic cells erythropoiesis occurs.  
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Causes of folic acid deficiency in pregnancy could be inadequate dietary 
intake, hyperemesis gravidarum, impaired absorption like with sprue. The 
average daily intake of folic acis is 120 to 300μg . 
 
Folic acid deficiency can affect the outcome of pregnancy in multiple 
ways causing abortion of the baby, premature deliveries, anomalous baby 
and maybe even antepartum hemorrhage. There has been studies 
demonstrating the association between folic acid deficiency and 
abruption.  
 
Clinical features: 
The time of onset of this variety of anemia is between 5 to 7 months of 
gestation. Atrophic glossitis, hepatosplenomegaly, purpura can be seen 
with other manifestations of anemia. Neurological manifestation is rare in 
pregnancy.  
 
In women on anticonvulsant drugs there occurs an increased deamand for 
folic acid as the anti epileptic drugs interfere with folate metabolism. 
Prolonged OCP intake prior to pregnancy can interfere with folic acid 
stores and present with a deficient state.  
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The neonate of a folate deficient mother is mostly delivered preterm. 
Periconceptional folic acid suppplmentation is essential to prevent the 
incidence of cleft lip, cleft palate, neural tube defects. 400μg of foli acid 
hence needs to be supplemented in the periconceptional period.  
 
When there is history of earlier child having neural tube defects these 
women can be administered therapeutic dosage of folic acid at 4mg 
concentration.  The prophylactic dosage of folic acid is advocated in all 
women as iron deficiency masks the folic acid deficiency and 
supplementation with just iron interferes with improvement of anemia 
and makes the anemia refractory to treatment.  
 
Other cause for megaloblastic anemia is B12 deficiency. This B12 
deficiency is common in medical disorders like tropical sprue. There is 
fall in B12 concentration in pregnancy as the B12 stores are diverted to 
support the nutrition of the fetus. Hence the levels B12 in cord blood 
tends to be higher than in maternal blood despite folate and B12 being 
transferred at the same rate through the placenta.  
 
In pregnancy, similar to iron binding capacity, B12 binding capacity is 
also increased and results in increased deposition of B12 in liver by the 
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protein transcobalamin. The stores of B12 are in the range of about 
3000μg in adults.  
 
Treatment: 
Treating a megaloblastic anemia is far more essential than correcting iron 
deficiency as the former is a far more dangerous entity than the latter. 
When megaloblastic anemia is proven it needs therapeutic dosing of folic 
acid in the dose of 5mg.  
 
Response of this therapy is evaluated in terms of fall in LDH levels which 
can occur over 3 to 4 days followed by a rise in reticulocyte count which 
can occur over 6 to 8 days.  
 
There is no indication for blood transfusion in megaloblastic anemia, the 
only indication being occurrence of antepartum hemorrhage. 
 
B12 deficiency can be corrected by administering 250μg of parenteral 
cyanocobalamin.  This is important because when the megaloblastic 
anemia is treated with folate without B12 supplementation it can lead on 
to exacerbation of the neurological symptoms.  
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APLASTIC ANEMIA: 
This is a condition where the bone marrow becomes incapable of 
producing blood cells and renders the patient anemic. When the diagnosis 
of aplastic anemia is made, pregnancy should be avoided. If the patient 
becomes pregnant, it needs to be terminated in early gestation or 
managed with transfusion of blood and blood products at a later 
gestation. 
 
HEMOGLOBINOPATHIES: 
Hemoglobin is a protein that has heme and globin component. The heme 
fraction is made up of various polypeptides. When there is defect in these 
polypeptide chains, it is called as hemoglobinopathy. 
 
The most common hemoglobinopathy is thalassemia. In beta thalassemia, 
the beta chains are not synthesized and hence the normal HbA is replaced 
by HbF or HbA2.  In case of alpha thalassemia, the alpha chains are 
defective and the conditions are called as thalassemia major, thalassemia 
minor, thallasemia intermiediate.  
 
The other hemoglobinopathy is sickle cell anemia where the hypoxic 
condition manifests as sickling of the red blood cells. This sickling can 
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obstruct blood vessels and manifest as dactylitis, bone pain and 
autosplenectomy.  
 
When the anemia is refractory to treatment, suspicion of other rare 
variants need to be made and diagnosis confirmed by making a bone 
marrow biopsy for aplastic anemia or smear study to identify sickling 
after adding a reducing agent. 
 
Management of hemoglobinopathies is mostly by blood transfusion and 
these conditions do not respond to iron or folic acid supplementation.  
 
These conditions are associated with obstetric complications like pre 
eclampsia, cardiac failure due to volume overload state of pregnancy. 
There can occur a high incidence of loss of pregnancy by abortions or 
intra uterine deaths of fetus, preterm premature deliveries, intrauterine 
restriction of growth of fetus as a result of the chronic placental 
insufficiency.  
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REVIEW OF LITERATURE 
       Breymann4 study showed that iron sucrose releases iron that has a 
half life of 6 hours with minimal allergic reactions, or overload 
complications. This resulted in iron sucrose being found to be a safe 
option for management of iron deficiency anemia.  
 
        Geisser et al showed that iron sucrose for parenteral administration 
and anemia correction is the ideal drug as it is safe and devoid of 
complications and cost effective.  
 
Moment et al studied by comparing iron sucrose with ferrous 
sulfate in terms of safety and efficacy. They conducted a prospective, 
open controlled study by randomly assigning women with anemia to iron 
sucrose group or ferrous sulfate group. The study sample included 52 and 
the control group consisted of 59 patients.  
 
In the study group, the administration dose was calculated by the 
formula Hb deficit in g/l * body weight in kg * 0.3. This calculated dose 
was administered by using 2 vials of iron sucrose containing 200mg of 
elemental iron in 100 ml of normal saline. This solution was administered 
intravenously slowly over a period of 1 hour. After completing the dose 
they were also given 10mg/kg of iron to improve the iron stores.  
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Among the control group, iron supplementation was done by giving 
30mg of ferrous sulfate tablets containing 60mg of elemental iron 8th 
hourly.  
 
Both the groups of patients were stringently observed for adverse effects 
and improvement of anemia clinically and by laboratory parameters. 
The reports of the study showed better outcome in the iron sucrose group 
with improvement in hemoglobin level of about 128.5 +/- 6.6g/L as 
opposed to 111.4+/-12.4g/L in the ferrous sulfate group. This 
improvement in hemoglobin status was achieved in 6.9+/-1.8 weeks in 
iron sucrose group when compared to 14.9+/-3.1 weeks in the ferrous 
sulfate group. Both these finding had a p value <0.001 proving a 
significant superiority of iron sucrose over ferrous sulfate.  
 
The side effect profile was analysed and found to be nil complaints in the 
iron sucrose group. On the contrary, the control group of ferrous sulfate 
users had 6% intolerance to the tablet, 30% dyspepsia, 30% poor 
compliance.  
The results of this study showed that iron sucrose is a safer and effective 
method to correct iron deficiency anemia.  
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Perwunyk et al studied the effect of iron sucrose therapy in 
reducing the need for blood transfusion. Iron sucrose has fewer side 
effects and insignificant allergic reactions, as the release of iron from the 
iron sucrose complex is slow. This slow release also decreased the 
storage of iron of in liver parenchyma as against increased storage of iron 
dextran or iron gluconate. The decreased parenchymatousstorage lead to 
increased deposition in bone marrow causing enhanced erythropoiesis. So 
among patients using iron sucrose the need for blood transfusion was less 
than 1% of patients per year.  
 
Al ra et al study was a randomized open labeled study that 
compared iron sucrose with oral iron for correcting iron deficiency. The 
study sample included 90 women who had hemoglobin levels in the range 
of 8 to 10.5g/dl. The inclusion criteria for the study required a ferritin 
level of less than 13mcg/L. The sample was divided into two groups and 
administered iron sucrose in the study group and oral iron polymaltose in 
the control group. The iron polymaltose tablet contains 300mg of 
elemental iron.  
 
The required dosing was calculated by the formula: 
Pre-pregnancy weight in kg * Hb deficit from 110g/l * 0.2 + 500mg 
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      The effect of treatment was assessed by repeating the hemoglobin and 
ferritin values on day 14, day 28, day of delivery, and postpartum day 
one. The associated adverse effects, weight of the baby, duration of 
hospital stay, need for blood transfusions were also analysed.  
 
The reports revealed a greater increase in hemoglobin levels in the study 
group comprising of intravenous iron sucrose administration as compared 
to control group of oral iron supplementation. On day 14, the hemoglobin 
improvement comparison between both groups gave a p value of 0.004 
while on day 28 the p value was 0.031.  
 
Ferritin values were compared to find the result of the study and it 
revealed better outcome in those receiving intravenous iron 
supplementation throughout the pregnancy period.  
There was no significant adverse effect in both groups. Likewise there 
was no variation in terms of weight of baby or duration of hospital stay.  
 
There was need for blood transfusion among oral iron group. This proves 
the advantage and superiority of intravenous iron sucrose in correcting 
iron deficiency anemia.  
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There was better correction of anemia in intravenous group receiving iron 
sucrose as they had better iron stores improvement at a faster rate and 
better efficacy without causing significant adverse effects.  
 
Al moment et al conducted another randomized prospective 
controlled study. The study sample in this was 111 women at various 
stages of pregnancy and hemoglobin level less than 9g/dl and proven iron 
deficiency anemia on smear study. This sample was randomly divided 
into two groups and 55 women were given intravenous iron sucrose and 
55 women were given intramuscular iron dextran.  
 
Iron sucrose was given as 100mg of elemental iron in 100ml of normal 
saline intravenously. Iron dextran was administered as 100mg 
intramuscular dose on alternate days upto a maximum of completing the 
calculated iron requirement.  
 
The reports of this study showed that better improvement of hemoglobin, 
with a shorter time duration was achieved with intravenous therapy 
compared to control group. The side effect profile was non existent in 
iron sucrose group. But 6% developed intolerance, 30% developed 
nausea, 32% turned no  compliant in the control group. 
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Wali et al conducted a prospective controlled study where they 
compared iron sucrose with intramuscular iron sorbitol. This study was 
done on 60 pregnant women. The inclusion criteria for the study was 12 
to 34 weeks of gestation and proven iron deficiency anemia.  
 
These patients were then randomly divided to three groups.  
15 women were given iron sucrose intravenously at a dose of  
pre-pregnancy weight in kg * Hb deficit from 110g/L * 0.24 +500mg. 
20 women were given iron sucrose intravenously at a dose of  
pre-pregnancy weight in kg * Hb deficit from 110g/L * 0.24 +200mg 
25 women were managed with intramuscular iron sorbitol.  
 
The effects of treatment was analysed by hemoglobin estimation after 3 
weeks of treatment. The hemoglobin increase was by about 2.8g/dl in the 
first group, 1.9g/dl in the second group and 1.4g/dl I the third group.  The 
total increase in hemoglobin was 3.8g/dl in the first group and 2.4g/dl in 
the second group over a period of 6.6.weeks.  
The end point was kept at achieving 11g/dl of hemoglobin levels. This 
end point was achieved in 80% patients in the first group, 70% patients in 
the second group, and only 28% in the third group.  
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The results of this study prove that the intravenous mode of 
administration is far effective method of anemia correction that is safe 
and convenient as compared to imtramuscular mode of iron 
administration.  
 
Hogine et al study involved comparison of iron sucrose with iron 
dextran in causing adverde effects. One set involved a sample of 206 
patients, of which allergic reaction to iron dextran occurred in 4 women.  
 
Among these allergic reaction, 1 patient manifested with severe 
dyspnea and the remaining 3 patients presented with generalized 
reactions.  
 
Another study was conducted at Zurich hospital involving 400 patients 
who required treatment with intravenous iron sucrose administration. 
Among this group, generalized skin reactions occurred in 7 women, 
flushing occurred in 4 women, exanthema occurred in 3 women.  
 
A reterospective was conducted among 8100 patientt years. They were 
managed with 100mg elemental iron each using up about 160,000 
ampoules of iron sucrose. Flushing occurred in 10 women, reversible 
hypotension occurred in 7 women, urticaria in 1, diarrhea in 1 woman.  
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Dede et al studied the correction of anemia occurring in postpartum 
period with iron sucrose. This study comprised of 75 women in their 
puerperal period who had hemoglobin levels of 9g/dl. This sample size 
was divided into two groups where one group was administered iron 
sucrose intravenously and another group was given oral tablets containing 
60mg of elemental iron on a 8th hourly basis. The effects were analysed 
by hemoglobin, ferritin, iron and hematocrit, TIBC estimation at day 7 
and day 28. The reports revealed significant improvement of serum 
ferritin levels within shorter time duration and fewer adverse profile 
among women managed with intravenous iron therapy rather than with 
oral iron therapy.  
 
Wali A, Mushtaq A performed a prospective study on 60 women 
who were 12 to 24 weeks pregnant. One group of 30 women received 
500mg of iron sucrose and another group of 30 women received iron 
dextran. The baseline hemoglobin was obtained and repeat hemoglobin 
estimation was done 3 weeks alter which showed a increase of 2.8g/dl in 
first group and 1.4g/dl in the second group. Adverse effects were 
analysed and it showed 1 complaint of abdominal pain, 2 complaints of 
shivering, 3 complaints of phlebitis in intravenous group. The 
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intramuscular group presented with injection site pain in almost all 
patients.  
 
Breyman et al conducted a prospective randomized trial for 
correcting iron sucrose anemia with iron sucrose with use or without use 
of recombinant human erythropoietin. The inclusion criteria in this study 
was more than 20 weeks of pregnancy with hemoglobin levels of less 
than 9g/dl. 20 patients belonging to first group were given 200mg iron 
sucrose intravenously and 300IU/kg recombinant human erythropoietin. 
20 patients belonging to second group were given biweekly injections of 
200mg iron sucrose for upto 4 weeks. Hematocrit values and reticulocyte 
counts were assessed in both groups and the reports revealed better 
outcome with erythropoietin therapy. There were no reports of adverse 
effects, no blood transfusion requirement. This study suggested usage of 
iron sucrose for correcting iron deficiency anemia initially in pregnancy 
and addition of erythropoietin in severe anemia that was not responding 
to intravenous iron sucrose.  
 
Scoff et al studied and reported that usage of intravenous iron 
therapy reduced the need for blood transfusion.  
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Sal Mommen et al studied iron sucrose therapy with ferrous 
sulphate and discovered that there was better improvement of hemoglobin 
levels in the range of 128.5+/-6.6 in intravenous group as compared to 
111.4+/-2.4g/dl in the ferrous sulphate group. There was no side effect 
reported with iron sucrose and 6% incidence of side effects with control 
group.  
 
Gravier et al conducted a study to identify ability of iron sucrose in 
reducing the need for postpartum blood transfusion and concluded that 
when pregnant mothers were treated with iron sucrose antenatally the 
need for postpartum blood transfusion was reduced and iron sucrose also 
has a better outcome in correcting postpartum anemia.  
 
Scott B, Silvestein study reported that the incidence of anaphylaxis 
was 0.002% following intravenous iron administration and 0.6-0.7% 
following intramuscular iron administration.  
 
         American College of Nursing Journal published a study citing the 
safety of iron sucrose usage in patients with cardiac disease along with 
anemia complication.  
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   ACOG Journal published a study reporting iron sucrose corrected 
anemia effectively without any adverse effects.  
       
 BJOG reported that the increase in hemoglobin levels was high with 
intravenous iron sucrose therapy and there also occurs replenishment of 
the iron stores.  
     
  European Journal issued a study citing the safety and efficacy of iron 
sucrose in correcting iron deficiency anemia.  
 
All these studies prove that irrespective of the ethnicity and racial 
differences intravenous iron sucrose is capable of correcting iron 
deficiency anemia clinically and also improve the hematologic indices in 
a safe efficacious way.  
 
In a study of Kriplani A et al on Intravenous iron sucrose therapy 
for moderate to severe anaemia stated that parenteral iron therapy was 
effective in increasing haemoglobin,serum ferritin and other 
haematological parameters in pregnant women with moderate anaemia 
 
Another study conducted on 50 pregnant anaemic women byKhurshid 
ShabbirRaja,NusratBatoolJanjua and NasirKhokhar stated that, Iron 
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sucrose complex when given to pregnant women with IDA significantly 
improved the haematological parameters 
 
In a study conducted by Abdul Kareem Al-Momen et al on 52 patients 
and 59 controls concluded that Iron sucrose therapy resulted in a 
significantly higher Hb level in a shorter period with no major side 
effects. Hence they stated that Iron sucrose therapy as safe and effective 
in the treatment of iron deficiency anaemia during pregnancy. 
 
Bhandal et al performed a study by randomized controlled trial method 
involving a total of 400 women in their postpartum period, with 
laboratory reports showing hemoglobin values less than 9g/dl, ferritn 
values being less than 15μg/L, in their postpartum period of 24 to 48 
hours post delivery.  
 
The sample was divided into two groups and admininstered intravenous 
iron sucrose in one group and oral ferrous sulphate in the control group. 
Both the groups showed a good improvement in their hemoglobin levels 
following therapy on day 5 and day 14 estimation.  
 
Westad et al performed another study by involving women from five 
different obstetric centres. This was a randomized controlled study done 
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on 129 women in their postpartum period. These women had a 
hemoglobin value in the range of 6.5 to 8.5g/dl and were in their 
immediate postpartum period of 48 hours post delivery.  
 
One group of women received intravenous iron sucrose while another 
group of women received oral ferrous sulphate. The follow up was done 
at 4, 8 and 12 weeks by withdrawing blood and estimating their 
hemoglobin values. This study report was issued as improvement of 
hemoglobin by 2g/dl in the treatment group following intravenous 
administration. 
 
Meghan Crowley et al performed a widespread study in the form of six 
trials involving a mammoth 1140 women. These studies yielded results as 
shortened duration of time to achieve improvement in hemoglobin levels 
when iron was supplemented intravenously.  
 
Both iron sucrose and ferric carboxymaltose were thus proven to be 
successful in managing anemia and improving the hemoglobin status of 
the patient. They also showed that both these being intravenous 
preparations had an edge over the oral preparations by eliminating the 
gastrointestinal side effects.  
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GUIDELINES FOR PREVENTION OF MATERNAL ANAEMIA 
Anemia is an important risk factor that affects the maternal morbidity and 
mortality and also influences the health of newborn and hence health 
promotion strategies were developed to prevent maternal anemia.     
Maternal anemia is associated with poor intra-uterine growth and 
conceiving of low-birth-weight babies and the incidence of abortion is 12 
to 28%, perinatal death is 30%, and neonatal death is 7 to 10%. There 
occurs a fivefold increase in preterm delivery and 15 to 20% incidence of 
maternal mortality in anemia complicating pregnancy. 
 
As anemia can significantly impair the health of the mother and cause 
maternal mortality and perinatla morbidity, the National Rural Health 
Mission issued guidelines to prevent anemia in pregnancy. 
 
Classification of Anaemia (ICMR-1989) 
Hb level   
Classification  
<4g/dl  Very severe  
4-6.9 g/dl  Severe  
7-9.9 g/dl  Moderate  
10-10.9 g/dl  Mild  
 
a. Compulsory Haemoglobin estimation  
Haemoglobin estimation is done by Cyanmeth-haemoglobin method at 
14-16 weeks, 20-24 weeks, 26-30 weeks and 30-34 weeks of pregnancy 
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mandatorily for all pregnant mothers. Repeat estimation of hemoglobin 
should be done with 4 week interval between estimations.  
 
b. Deworming at 14-16thweek of gestation  
Deworming is done with one tablet of albendazole in all women at 14 to 
16 weeks of pregnancy.  
 
I. At 14-16 weeks  
First Hb estimation is done at 14-16thweek for all the antenatal mothers. 
At Hb levels more than 11g, prophylactic dose of iron folic acid tablet 
with 100m iron and 0.5mg of folic acid supplementation is sufficient. 
These tablets are administered daily for 100 days. When the Hb levels are 
between 7 to 11g, therapeutic dose of iron folic acid tablets administered 
by giving the tablets twice daily.  When he hb levels are less than 7g, 
patient needs blood transfusion and further evaluation for cause of 
anemia.  
 
 II.At 20-24 weeks  
Second estimation of hemoglobin is done between 20 and 24 weeks  
At Hb levels more than 11g, prophylactic dose of iron folic acid tablets 
are sufficient. When the Hb levels lie between 9-11g, the same tablets are 
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administered at therapeutic dose of twice daily. When the Hb levels are 
between 7 to 9g, iron sucrose is administered intravenously at a dose of 
100mg of elemental iron containing iron sucrose is mixed in 100ml of 
normal saline and administered slowly over 20 to 30 minutes on alternate 
days upto 4 doses. Oral iron supplementation should be discontinued 
when using intravenous supplementation. When the Hb levels fall below 
7g, blood transfusion is required.  
 
III. At 26-30 weeks  
Next hemoglobin value is done at 26 to 30 weeks of gestation. But when 
there has been history of iron sucrose administration, the estimation 
should be done one month after last dose.  
When Hb levels are more than 11g, patient can continue with 
prophylactic dose of iron folic acid tablets. When the Hb levels come to 9 
to 11g, there need to be a changeover to therapeutic dose of iron folic 
acid tablets. When the Hb levels become 7 to 9g, if there is history of iro 
sucrose administration, two top up doses of iron sucrose is sufficient. If 
there is no history of iron sucrose usage, start the patient on 4 doses of 
iron sucrose administration intravenously over a period of 2 weeks. At 
Hb levels less than 7g, patient needs to be managed with blood 
transfusion.  
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IV. At 30-34 weeks  
Irrespective of previous anemia management all pregnant women need 
Hb estimation at 30-34 weeks.  
At Hb levels more than 11g, continue prophylactic iron supplementation. 
At Hb levels of 9 to 11g, manage with therapeutic iron dosage. If Hb 
levels do not improve more than 9g at 30-34 weeks of gestation there is a 
need to correct anemia with blood transfusion.  
 
b) History  
a. History of blood transfusions repeatedly point to hemoglobinopathies 
and bleeding disorders.  
b. Rule out any history of drug allergy or bronchial asthma.  
Avoid injection iron sucrose if there is positive history.  
 
 
c) Tests to be done  
Hb estimation by Cyanmeth-hemoglobin method    
Peripheral smear for cell morphology 
MCV/RBC ratio 
Serum iron binding capacity   
Urine should be checked for albumin, sugar and deposits and urine 
culture to be done if there is presence of 4-6 cells 
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d) Safety aspects  
Iron sucrose infusion has to be administered as 20-30 drops per minute in 
the first 5 minutes, and then increased to 80-90 drops per minute and 
completed in 30 minutes to avoid free radical release. Administering the 
iron sucrose injection should be done cautiously to avoid extravastation 
of drug. Standard Emergency tray should be made available at the 
 bedside for handling any reactions.  Pulse and BP to be recorded 
before, during and after the administration of Inj. Iron Sucrose infusion 
  
 
e)Dietcounselling 
All the mothers should be encouraged to take iron rich foods and avoid 
coffee and tea.  
 
f)Vitamin supplementation Water soluble vitamins like folic acid, 
B12 need not be withheld during iron sucrose infusion.  
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AIMS AND OBJECTIVES 
 
1. To evaluate the response and effect of intravenous iron sucrose 
complex given to pregnant women with IDA. 
2. To study the acceptance of drug among anemic mothers 
3. To study the side effects of the drug 
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MATERIALS AND METHODS 
 
STUDY SETTING: Govt. Theni Medical College and Hospital, 
Department of Obstetrics and Gynaecology 
 
STUDY DESIGN :prospective randomized control study 
 
SAMPLE SIZE: determined by statiscal analysis 
100 pregnant women with haemoglobinbetwwen 7-9% with diagnosed 
iron deficiency attending antenatal clinic,were given intravenous iron 
sucrose complex in a dose of 200mg twice weekly schedule after 
calculating dose requirement 
 
DURATION OF STUDY: one year study From July 2015 to June 2016 
 
INCLUSION CRITERIA 
      Age  18-40yrs  
       Pregnancy between 18 to 24weeks 
       Hb 7-9 gm% 
 
EXCLUSION CRITERIA 
         Underlying disease such as heart disease, hypertension 
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         H/o allergy to iron metabolism 
         Hb <7g%  
         Thalassemia 
         Bleeding diathesis 
 
METHODOLOGY: 
Red cell indices, peripheral blood smear and detailed serum iron studies 
were also conducted.  
100 women were recruited for intra venous iron sucrose therapy. Ethical 
clearance for the study protocol was taken from the Ethics Committee of 
the institute. Informed written consent was taken from all the patients 
before starting the therapy.  
Baseline investigations including liver and kidney function tests, urine 
(routine microscopy and culture sensitivity), stool examination (for ova 
and cyst) were done. Folic acid tablets were given to all women during 
therapy.  
 
The formula used for calculation of iron sucrose dose was as follows:    
Required iron dose (mg) = (2.4 x (target Hb-actual Hb) pregnancy 
Weight(kg) 
                                               + 1000 mg for replenishment of stores 
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The required iron dose varied depending upon index Hb level and pre-
pregnancy weight. Average dose requirement was 1777 ± 168.5 mg 
(1400-2160 mg). Mean duration to complete total therapy was 4.5 ± 1.0 
(3.5-5.5 wk).  
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RESULTS: 
 
Age Distribution (Table 2) 
 
 
 
                
 
                                                 
 
 
INFERENCE 
         Among 100 patient studied 29% were less than 18 yrs,58%belong 
to age group of 21-25 yrs,13% belong to 26 to 30 yrs. 
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TABLE 3 
Booking Status 
 
 
INFERENCE: 
                          Among 100 patients 28% were booked case and 72% 
were unbookedcase.with iron sucrose therapy given  more to unbooked 
cases than booked cases. 
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Table 4 
Obstetric Code 
 
 
 
 
 
INFERENCE: 
                      Among 100 patients 52%  are primigravida,40% gravida 2, 
5% gravida 3 , 3 % gravid 4. With mean parity  
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Table 5 
Socio Economic Status 
 
 
 
 
 
 
INFERENCE: 
 
7% belong to class 3, with 45% belong to class 4,48% belong to class v. 
with mean socioeconomic status  
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Table 6 
clinical features 
 
 
 
 
INFERENCE: 
 
Symptom of  easyfatiguability and pallor 52% which was in higher 
number than pallor alone or easy fatiguability,pallor and breathlessness. 
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Table 7 
Gestational Age 
 
 
 
 
Gestational age at delivery: 
 
Among 100 patient studied, 12 % were preterm and  88% term gestation 
deliveries 
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Table 8 
Reticulocyte count 
 
 
 
 
 
pretreatment reticulocyte count :1.165 
posttreatment reticulocyte count:4.098 
changes in reticulocyte count:2.93 
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Table 9 
MCV 
 
 
 
pretreatment mcv:68.59 
posttreatment mcv:85.94 
changes in mcv:17.35 
after 3 weeks of therapy rise in mcv of 17.35 is significant 
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 Table 10 
Haematocrit 
 
 
pretreatmenthaematocrit: 23.59 
posttreatment hematocrit:33.60 
changes:5.01 
after 3 weeks of therapy rise in hematocrit 5.01 is significant 
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RESULTS 
Mean age of women was 23.46 ± 3.1 (range 18-30) yrs 
Mean parity was 2. 
At the beginning, mean Hb was 7.51 ± 0.60 g%.. 
After completion of therapy, mean Hb raised to 10.9 ± 0.8 g%.  
Of the total women. The mean duration to achieve haemoglobin level 
more than 11 g% was 6.5 ± 2.3 wks 
SIDE EFFECTS OF THERPY 
Thromobophlebitis 
Giddiness and restlessness 
Mild fever 
There were no major anaphylactic reactions 
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DISCUSSION: 
 
Iron deficiency anemia is an important health concern for everyone, more 
so among pregnant women all over the world. The redeeming feature in 
this anemia is that it has tremendous response to iron supplementation. 
The factors causing iron deficiency anemia are present even before 
pregnancy, right from when the female attains menarche. The blood loss 
occurring during menstruation, inadequate and poor nutrition, poor 
bioavailabilty of the dietary iron when added with the requirement of 
pregnancy can lead on to iron deficiency anemia. It has been postulated 
that many women are in iron depleted state at the start of their 
pregnancy21. 
 
The iron supplementation is done parenterally when the anemia is severe 
of oral supplementation is inadequate22. Also parenteral supplementation 
is required when the woman has defective absorption of oral iron due to 
various conditions like inflammatory bowel disease, ferrous intolerance23.  
In our study population of  100 antenatal patients attending GTMCH 
OPD between 18-24 weeks of gestation ,clinical features and laborartory 
parameters were evaluated and results are statistically analysed.of the 
population studied,majority of them were between 21-25 yrs age group 
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accounting for 58% followed by 29% below 20yrs and 13% between 26-
30yrs of age. 
 
Many studies showed that iron sucrose brought about a faster increase in 
hemoglobin levels as compared to oral iron supplementation. They also 
showed that only iron sucrose was capable of improving iron reserves.  
 
The improvement in serum ferritin levels was showed not to be because 
of administering iron directly intravenously. The mechanism was 
explained to be due to rapid release of iron from the iron sucrose complex 
and this enabling the binding of this iron to the transport proteins found in 
human body. These proteins carry the iron and deposit them in 
parenchymatous tissues and enable them to be used up at a later date.  
  
Out of 100 patients ,72 ‘percentage of anemic patients were unbooked 
and 28% were booked in a hospital.of the total study group of 100 
mothers,52% were primigravida followed by 40% second gravida,5% 
third gravid and 3 5 fourthgravida. 
   
 Majority of the anemic population belonged to class 5 and class 4 
socioeconomic status accounting for 48 and 47 percentage respectively 
whereas only 3 percent belonged to higher socio economic class. 
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About 52% of the patients had easy fatiguablitity as their presenting 
symptom followed by 30% of the patients who were identified by pallor 
sign and 15% had breathlessness as complaint. 
 
    On following these 100 patients ,we could observe that about 88% 
reached term  and 22% had preterm delivery. 
  
 On observing laboratory investigations,we could conclude that there is a 
marked rise in reticulocyte count  of about 2.093% ( pretreatment -
1.165% post treatment-4.098%) following 3 weeks of iron sucrose 
injections which is statistically proven as significant. 
The pretreatment MCV is 68.5 and post treatment MCV 85.94% with 
changes after three weeks is 17.35% and hematocrit before treatment is 
23.59 and post treatment 33.6 with changes 5.01 is analysed as significant 
statistically. 
 
There was a cent percent improvement of clinical symptoms following 
iron sucrose therapy. 
 
    Only minor adverse reactions caused by iron sucrose.No major 
reaction 
69  
 
 
Changes in hemoglobin: 
In this study intravenous iron sucrose was administered to women and the 
result of treatment was verified by estimating the baseline hemoglobin 
and repeat estimation 3 weeks after the therapy. The pretreatment 
hemoglobin levels of women participating in this study was 7.51±0.60g 
and the repeat hemoglobin values were 10.9±0.81g. 
This was comparable to a study done by Bayomeu et al24 where the resuls 
obtained showed rise in hemoglobin values from 9.6±0.7g to 11.11±1.3g 
at 4 weeks of therapy.  
Another study was conducted by Westad by randomized controlled trial 
which reported improvement in postpartum anemia in about 128 women 
by administering intravenous iron sucrose and showed a rise in 
hemoglobin from 6.5g before treatment to 11.g after 4 weeks of therapy.  
 
Rosario et al studied the influence of intravenous iron sucrose in women 
presenting with anemia following childbirth or surgery and found that the 
rise in hemoglobin was an additional 2.1g/dl following intravenous 
administration.  
 
Patel et al5 studied the influence of iron supplementation both in antenatal 
and postnatal women and he reported that the rise in hemoglobin was 
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about 7.9 on day 0 to 9.25 on day 8 and 11.6g on day 15 following 
therapy.  
When administered among postnatal women the rise in hemoglobin was 
from 7.9g on day 0 to 9.4 on day 8 and 11.2g on day 15 following 
intravenous iron sucrose.  
 
All these studies show that the administration of iron sucrose plays an 
important role in improving the hemoglobin status of women both 
antenatally and postnatally.  
 
changes in hematocrit: 
Hematocrit estimation was done in the study 3 weeks after administration 
of intravenous iron sucrose. This hematocrit is an indicator of 
improvement of hemoglobin status and in our study time taken for 
improvement was 3 weeks.  
 
Seid et al studied the effect of iron sucrose in imporving hemoglobin by 
2,6g/dl and found that the time taken to achieve this improvement was 4 
weeks.  
 
Likewise another study was conducted comparing iron sucrose with ferric 
carboxymaltose and it showed the latter drug brought about a greater 
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increase in hemoglobin values in shorter duration of time. But 
carboxymaltose being far more costly than iron sucrose is a big 
disadvantage.  
 
The study concluded that iron sucrose is a cost effective method to 
improve hemoglobin and that it is superior to oral iron supplementation 
for the same purpose.  
 
Bhandal and Russel performed a randomized controlled study to compare 
oral iron with intravenous iron in management of postpartum anemia. 
They reported that in the short term intravenous iron provided better 
improvement of hemoglobin levels as against oral iron supplementation, 
But this advantage was lost as by day 40, the hemoglobin increase was 
similar in both groups. 
 
 Breymann et al conducted a study involving 129 pregnant women with 
anemia with hemoglobin values less than 9g/dl and proved that 
intravenous iron sucrose administration improved the hemoglobin levels 
by about 2g% and this outcome was evident by 4 weeks of therapy.  
 
Westad et al studied the time taken for rise in hemoglobin and correction 
of anemia following intravenous iron administration and found that a 
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target of 11g Hb was achieved in 80% of individuals treated with iron 
supplementation intravenously.  
 
They also found that iron supplemented got incorporated into hemoglobin 
after about 3 to 4 weeks and this was why there occurred a delayed 
increase in hemoglobin following iron therapy.  
 
Al moment et al showed that iron sucrose resulted in greater 
improvement of hemoglobin values in about 3 weeks duration.  
 
Changes in mcv: 
In our study mean mcv value as.after 3 weeks showed improvement 
as.rise in mcv 
 
Adverse reactions: 
5 % treated with iron sucrose showed minor adverse reaction. 
1.giddiness nd restlessness. 
2.mild fever 
3.thrombophlebilitis 
      There were no major anaphylaxis reaction. 
Similar reports were also presented by al moment et al who compared 
intravenous iron sucrose with oral preparations and found that there was 
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no incidence of adverse effects when women were admininstered iron 
sucrose as against non compliance, gastrointestinal side effects and 
nausea found in the group treated with oral iron.  
 
Hogine et al performed another study comparing the adverse reactions 
occurring following iron sucrose and intramuscular iron and found no 
adverse reactions following iron sucrose but severe pain and hence poor 
compliance following intramuscular iron administration.  
 
Various factors play an important role in affecting the effects of 
treatment.  In our study the hemoglobin values improved considerably 
without any difficulty. 
 
Caretti et al study showed that the increase in hemoglobin was inversely 
dependent on the baseline hemoglobin value. He postuluated that low 
baseline values tend to respond more favourably.  
 
He also mentioned that the improvement was better when used after 7 
months of gestation rather than in early second trimester. This effect of 
period of gestation on anemia correction has been attributed to the 
influence of physiological hemodilution occurring in second trimester.  
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All these studies show that when the baseline value is lower and the onset 
of anemia is at a later period of gestation, the improvement of 
hemoglobin levels tend to be better with intravenous iron 
supplementation than oral iron.  
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  Summary 
In our study 100 patientswith iron deficiency anaemia  of GTMCH  OP 
department was followed from june 2015 to july 2016.patient selected 
according to inclusion and exclusion criteria already stated. 
 
The result of the study as follows: 
1.majority of patients ,around belonged to age group 21- 25 yrs 
2.unbooked patient received more iron sucrose than booked patients. 
3.majority of patients belonged to class 4 
4. primigravida affected more than multigravida 
5.symptoms like easy fatiguability,pallor ,breathlessness seen on 
examination 
6.symptomatic improvement seen in 100% of patients 
7.Mean rise in Hb seen as with iron sucrose 2.5g% 
8.Mean rise in reticulocyte count observed as 2.093% 
9.Mean rise in mcv seen with iron sucrose 17.35 
10.the adverse effect not observed in all 
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Conclusion 
Intavenous iron sucrose is safe in pregnancy. It corrects anaemia in short 
duration and replenishes iron stores better than oral iron. As the rate of 
increase in Hb is faster IV iron sucrose is suitable for treatment of 
anaemia in 2nd trimester. There was significant difference in ferritin level 
after treatment with oral & parenteral iron. With iron reserves restored 
only in the iron sucrose group. It has half life of about six hours. This is 
an advantage of iv iron sucrose over iron dextran. Anaemia was corrected 
satisfactorily without the use of weight dependent formula. Mild adverse 
events noted were Vomiting, giddiness, rashes following first dose. 
Because there was no serious adverse drug reaction and no anaphylaxis, 
we feel its safer for treatment of anaemia in pregnancy. 
It is accepted that iv iron sucrose therapy gives a rapid erytropoitic 
response in short duration. The rate of Fedelivery to bone marrow is a 
major factor for erythropoiesis. It rises the Hb at faster rate. Iron sucrose 
is definitely the first line of treatment for anemia in pregnancy in view of 
easy accesiblity, safety good efficacy compared to othe parenteral iron 
and blood transfusion. 
As compared to western women whose iron stores are sufficient and they 
need 30-40 mg of elemental iron for anaemia prophylasis in pregnancy. 
The stores in Indian women is deficient. And the need 100mg elemental 
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Fe for prophylaxis, it reduces the need for blood transfusion, and can be 
given as an outpatient basis. 
 
Intravenous iron sucrose is effective in improving 
Hb,hematocrit,mcv,reticulocyte count in short duration. 
It is safe with no adverse reaction 
 Thus it is concluded that intravenous iron sucrose is 
safe,effective,without any adverse reaction. 
IV iron sucrose therapy effective to treat moderate anemia in pregnant 
women .It causes rapid rise in Hb and replacement of stores fast 
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